FDA grants priority review to omidubicel for stem cell transplant to treat blood cancers

The FDA granted priority review to omidubicel, an investigational donor-based stem cell therapy for patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation.
Omidubicel (Gamida Cell) is an ex vivo-expanded, cryopreserved graft derived from an entire cord blood unit.
The therapy uses Gamida Cell’s proprietary nicotinamide-based expansion technology that enables donor cells to grow while maintaining functionality. The final cryopreserved product — administered via IV — includes nicotinamide-expanded hematopoietic stem cells and

The FDA granted priority review to omidubicel, an investigational donor-based stem cell therapy for patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation.
Omidubicel (Gamida Cell) is an ex vivo-expanded, cryopreserved graft derived from an entire cord blood unit.
The therapy uses Gamida Cell’s proprietary nicotinamide-based expansion technology that enables donor cells to grow while maintaining functionality. The final cryopreserved product — administered via IV — includes nicotinamide-expanded hematopoietic stem cells and